NHS England and NHS Improvement aim to complete the process to determine the location of a second provider to deliver transcranial magnetic resonance guided focused ultrasound services before the end of 2021/22. Until the location has been agreed, patients will continue to access assessment and treatment at the established centre in London.

NHS England and NHS Improvement commissioned this service in April 2021, therefore the number of patients who will be eligible for this treatment is uncertain. NHS England and NHS Improvement anticipate a level of patient backlog, as a result of patients who are suitable for treatment waiting for the service to be established. Capacity for provision of service in the first year has therefore taken this into account. The actual demand will be closely monitored in the first few years to better inform future commissioning.

NHS England and NHS Improvement aim to complete the process to determine the location of a second provider to deliver transcranial magnetic resonance guided focused ultrasound services before the end of 2021/22. Until the location has been agreed, patients will continue to access assessment and treatment at the established centre in London.

NHS England and NHS Improvement commissioned this service in April 2021, therefore the number of patients who will be eligible for this treatment is uncertain. NHS England and NHS Improvement anticipate a level of patient backlog, as a result of patients who are suitable for treatment waiting for the service to be established. Capacity for provision of service in the first year has therefore taken this into account. The actual demand will be closely monitored in the first few years to better inform future commissioning.

Significant progress has been made in the delivery of the commissioning policy for transcranial Magnetic Resonance Guided Focused Ultrasound (MRgFUS), published in November 2020 and effective from 1 April 2021.

MRgFUS is used in the treatment of medication refractory essential tremor. It has been estimated that there will be approximately 150 cases a year which, in the first instance, will require two centres to meet the needs of the population of England. A centre at Imperial Healthcare NHS Trust in London has already been identified and it is intended that this service will commence in May.

A second centre in the North of England will be required and discussions are ongoing with commissioners about its possible location. It is envisaged that there will need to be a formalised provider selection process given the number of expressions of interest received. Cross-border discussions have taken place with the devolved authorities in Scotland as to the feasibility of a third centre being commissioned in Scotland, and these discussions continue.

Significant progress has been made in the delivery of the commissioning policy for transcranial Magnetic Resonance Guided Focused Ultrasound (MRgFUS), published in November 2020 and effective from 1 April 2021.

MRgFUS is used in the treatment of medication refractory essential tremor. It has been estimated that there will be approximately 150 cases a year which, in the first instance, will require two centres to meet the needs of the population of England. A centre at Imperial Healthcare NHS Trust in London has already been identified and it is intended that this service will commence in May.

A second centre in the North of England will be required and discussions are ongoing with commissioners about its possible location. It is envisaged that there will need to be a formalised provider selection process given the number of expressions of interest received. Cross-border discussions have taken place with the devolved authorities in Scotland as to the feasibility of a third centre being commissioned in Scotland, and these discussions continue.

Significant progress has been made in the delivery of the commissioning policy for transcranial Magnetic Resonance Guided Focused Ultrasound (MRgFUS), published in November 2020 and effective from 1 April 2021.

MRgFUS is used in the treatment of medication refractory essential tremor. It has been estimated that there will be approximately 150 cases a year which, in the first instance, will require two centres to meet the needs of the population of England. A centre at Imperial Healthcare NHS Trust in London has already been identified and it is intended that this service will commence in May.

A second centre in the North of England will be required and discussions are ongoing with commissioners about its possible location. It is envisaged that there will need to be a formalised provider selection process given the number of expressions of interest received. Cross-border discussions have taken place with the devolved authorities in Scotland as to the feasibility of a third centre being commissioned in Scotland, and these discussions continue.